[Zolpidem (ivadal) treatment of sleep disorders].

The results of the multicenter study of zolpidem activity, being carried out in inpatient- and out-patient clinics of 20 cities in Russia, are reported. One thousand seventeen patients with transitory, short time and chronic dyssomnia have been included in the trial. Zolpidem (ivadal, "Sanofi-Syntelabo", France) has been prescribed once a day in a dose of 10 mg (one tablet) before going to sleep in a period of two weeks. The efficiency has been assessed by evaluating dyssomnia symptoms according to "Sleep assessment questionnaire" of "Sanofi-Syntelabo" completed by the patients and "Clinical Global Impression Scale" completed by investigators. Safety has been assessed by analyzing a frequency of side effect appearance and changes in vital parameters: blood pressure, heart and breath rate. Zolpidem has been found to reveal high clinical efficiency and safety. By the end of the treatment, 59.5% of the patients experienced no difficulties in falling asleep, in 28.6% of the patients the latter being significantly reduced. On the whole the improvement was in 89.4% patients. No side effects have been observed. Zolpidem is a highly effective and safe medication for different type dyssomnia treatment that can be recommended for application in general clinical practice.
AuthorsIu A Aleksandrovskiĭ, V V Androsova
JournalZhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoĭ promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe obshchestvo nevrologov [i] Vserossiĭskoe obshchestvo psikhiatrov (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 101 Issue 9 Pg. 22-6 ( 2001) ISSN: 1997-7298 [Print] Russia
Vernacular TitlePrimenenie zolpidema (ivadala) pri lechenii narusheniĭ sna.
PMID11586699 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • GABA Agonists
  • Hypnotics and Sedatives
  • Pyridines
  • zolpidem
  • Adolescent
  • Adult
  • Aged
  • Chronic Disease
  • GABA Agonists (administration & dosage, therapeutic use)
  • Humans
  • Hypnotics and Sedatives (administration & dosage, therapeutic use)
  • Middle Aged
  • Pyridines (administration & dosage, therapeutic use)
  • Sleep Wake Disorders (diagnosis, drug therapy)
  • Surveys and Questionnaires
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: